Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF.

Journal

Cleveland Clinic journal of medicine
ISSN: 1939-2869
Titre abrégé: Cleve Clin J Med
Pays: United States
ID NLM: 8703441

Informations de publication

Date de publication:
12 Aug 2020
Historique:
pubmed: 6 8 2020
medline: 6 8 2020
entrez: 6 8 2020
Statut: aheadofprint

Résumé

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.

Identifiants

DOI: 10.3949/ccjm.87a.ccc057 PMID: 32753517
pubmed: 32753517
pii: ccjm.87a.ccc057
doi: 10.3949/ccjm.87a.ccc057
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

Auteurs

Leonard H Calabrese (LH)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic calabrl@ccf.org.

Tiphaine Lenfant (T)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute Department of Infectious Disease, Cleveland Clinic; Assistance Publique des Hôpitaux de Paris, Université de Paris; Hôpital européen Georges Pompidou, Service de médecine interne, Paris, France.

Cassandra Calabrese (C)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, and Department of Infectious Disease, Cleveland Clinic.

Classifications MeSH